Stifel analyst Thomas M. Stephan raised the price target on Globus Medical (NYSE: GMED) to $95.00 (from $90.00) while maintaining a Hold rating.

The analyst comments "1Q26 sales were relatively solid and above Street—expectedly driven by strong core Musculoskeletal, as ET finished in-line and Nevro deteriorated. Despite the beat, management maintained sales guidance (Nevro offsetting core). • EPS was the 1Q26 standout at $1.12, and guidance increased by $0.30—more than the ~$0.20 1Q beat. • Coming into earnings, we noted we were warming up to the stock—but we still struggle a bit with what to do with shares here. On one hand, margins/earnings are robust and durable +DD% EPS growth is not difficult to envision, accompanied by impressive FCF conversion. • However, more near-term, (a) we now see even less 2026 sales upside potential (has been a consistent concern of ours) with Nevro/ET softening, which potentially limits the magnitude of an EPS beat-and-raise cadence this year and (b) 2H comps become much more challenging (hitting growth "optics")—all creating a potentially tricky setup for a relatively expensive stock (P/E basis)."